Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Source: Benzinga
Regeneron Acquires 23andMe Assets: Regeneron Pharmaceuticals has won a $256 million bid for key assets of 23andMe, including its Personal Genome Service and Biobank, to enhance its genetics-based drug discovery efforts while ensuring consumer services remain uninterrupted.
Commitment to Privacy and Ethical Data Use: Regeneron has pledged to uphold 23andMe's privacy policies and will have a Customer Privacy Ombudsman oversee data use, emphasizing ethical practices in leveraging genomic research for health advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 614.730
Low
637.00
Averages
808.50
High
1057
Current: 614.730
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment
- Program Selection and Adjustment: Sensorion SA announced the selection of SENS-601 as the lead program for treating GJB2-related hearing loss while discontinuing the Audiogene trial for SENS-501, resulting in a more than 15% drop in stock price on Wednesday.
- Gene Therapy Potential: SENS-601 is an AAV-based gene therapy designed to treat GJB2-related hearing loss, with the potential to address pediatric congenital deafness and early-onset presbycusis in adults, filling a market gap with no currently approved therapies.
- Clinical Trial Applications: The company has applied to initiate Hearconnex clinical trials in Canada and France, receiving Fast Track designation from the French National Agency for Medicines and Health Products Safety, aimed at evaluating the safety and efficacy of SENS-601 in pediatric patients.
- Resource Reallocation: Following the FDA approval of Regeneron's Otarmeni gene therapy, Sensorion opted to redirect resources towards the development of SENS-601, demonstrating the company's strong commitment to addressing GJB2-related hearing loss treatment.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial for treating advanced melanoma failed to achieve statistical significance on the primary endpoint, potentially impacting the market prospects of its drug candidates.
- Significant Stock Price Drop: Following the disappointing trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future performance.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Parabilis Medicines Plans $476M IPO Amid Regeneron Collaboration
- Fundraising Plan: Parabilis Medicines aims to raise up to $476 million through its initial public offering (IPO) in the U.S., with shares priced between $17.00 and $19.00, potentially reaching $476.4 million if underwriters fully exercise their overallotment option.
- Equity Offering: The company plans to issue 25 million shares of common stock, expecting net proceeds of $413.6 million at the midpoint, which will significantly support its ongoing research and market expansion efforts.
- Valuation Outlook: At the top of the IPO price range, Parabilis could achieve a valuation of up to $2.2 billion, establishing a strong market foundation for its future developments in cancer therapies.
- Collaboration Context: Regeneron has agreed to purchase approximately $75 million in company shares at a 10% discount, as part of a concurrent private placement linked to a research collaboration worth up to $2.3 billion, reflecting confidence in Parabilis's future potential.
See More
Intellia Therapeutics Shows Significant Progress, Stock Up 58%
- Clinical Trial Resumption: Intellia Therapeutics successfully resumed its clinical trials after overcoming a temporary hold by the FDA on two phase 3 studies, resulting in a 58% increase in stock price year-to-date, reflecting market confidence in its future potential.
- Gene Editing Therapy Effectiveness: In a recent phase 3 clinical trial, patients treated with lonvo-z experienced an 87% reduction in attacks, with 62% completely attack-free, indicating significant efficacy in treating hereditary angioedema and potential to become the standard of care.
- Substantial Market Opportunity: Although the hereditary angioedema patient population is only about 7,000 in the U.S., lonvo-z could represent a market size of $7 billion, with estimated lifetime sales of $3.5 billion at a 50% penetration rate, highlighting its commercial appeal.
- Future Growth Potential: Intellia is also developing nex-z for transthyretin amyloidosis, with a patient population of 250,000 to 500,000 globally; successful clinical trials could further enhance the company's stock price and market position.
See More
Intellia Therapeutics' Drug Phase 3 Trial Success
- Clinical Trial Success: Intellia Therapeutics' lonvo-z achieved positive results in a phase 3 trial for hereditary angioedema, with an 87% reduction in attacks after a single infusion, demonstrating the drug's efficacy and market appeal.
- Market Potential Assessment: Although the patient population for lonvo-z is only about 7,000, with a treatment cost of $1 million, its total addressable market in the U.S. could reach $7 billion, suggesting a potential lifetime sales of $3.5 billion, reflecting significant commercial value.
- Regulatory Progress: Intellia has begun submitting its application to the FDA for lonvo-z approval, aiming for a launch in the first half of 2027, which could establish it as the standard of care for hereditary angioedema and enhance the company's market position.
- Future Development Risks: Despite lonvo-z's promising outlook, Intellia faces clinical and regulatory risks, particularly with its other candidate nex-z, which has been put on clinical hold by the FDA, necessitating cautious evaluation of potential volatility by investors.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
Sensorion Selects SENS-601 as Lead Program for Hearing Loss Treatment
- Program Selection and Adjustment: Sensorion SA announced the selection of SENS-601 as the lead program for treating GJB2-related hearing loss while discontinuing the Audiogene trial for SENS-501, resulting in a more than 15% drop in stock price on Wednesday.
- Gene Therapy Potential: SENS-601 is an AAV-based gene therapy designed to treat GJB2-related hearing loss, with the potential to address pediatric congenital deafness and early-onset presbycusis in adults, filling a market gap with no currently approved therapies.
- Clinical Trial Applications: The company has applied to initiate Hearconnex clinical trials in Canada and France, receiving Fast Track designation from the French National Agency for Medicines and Health Products Safety, aimed at evaluating the safety and efficacy of SENS-601 in pediatric patients.
- Resource Reallocation: Following the FDA approval of Regeneron's Otarmeni gene therapy, Sensorion opted to redirect resources towards the development of SENS-601, demonstrating the company's strong commitment to addressing GJB2-related hearing loss treatment.
See More
Pomerantz LLP Investigates Regeneron for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Regeneron Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to legal repercussions.
- Disappointing Clinical Trial Results: On May 15, 2026, Regeneron announced that its Phase 3 trial for treating advanced melanoma failed to achieve statistical significance on the primary endpoint, potentially impacting the market prospects of its drug candidates.
- Significant Stock Price Drop: Following the disappointing trial results, Regeneron's stock price fell by $68.57, or 9.82%, closing at $629.68 on May 16, 2026, reflecting market concerns about the company's future performance.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Parabilis Medicines Plans $476M IPO Amid Regeneron Collaboration
- Fundraising Plan: Parabilis Medicines aims to raise up to $476 million through its initial public offering (IPO) in the U.S., with shares priced between $17.00 and $19.00, potentially reaching $476.4 million if underwriters fully exercise their overallotment option.
- Equity Offering: The company plans to issue 25 million shares of common stock, expecting net proceeds of $413.6 million at the midpoint, which will significantly support its ongoing research and market expansion efforts.
- Valuation Outlook: At the top of the IPO price range, Parabilis could achieve a valuation of up to $2.2 billion, establishing a strong market foundation for its future developments in cancer therapies.
- Collaboration Context: Regeneron has agreed to purchase approximately $75 million in company shares at a 10% discount, as part of a concurrent private placement linked to a research collaboration worth up to $2.3 billion, reflecting confidence in Parabilis's future potential.
See More
